Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

2024-9-5

Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination

2024-8-19

Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review

2024-8-7

Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy

2024-8-2

Durability of Response with First-Line Combined Immune Checkpoint Inhibitor Therapy Compared to Checkpoint Inhibitor with VEGFR-TKI in Advanced Clear Cell Renal Cell Carcinoma

2024-6-21

Patient Selection for Active Surveillance for Small Renal Masses: A Systematic Review of the Literature

2024-5-7

Papillary Renal Cell Carcinoma: Current Evidence and Future Directions

2024-5-7

Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis

2024-2-29

Clinical Trials Corner: Is the Era of Theranostics Imminent?

2024-2-20

Clinical Trials Corner: The dreaded IVC thrombus - optimizing management

2024-2-20

Molecularly Defined Renal Carcinomas

2024-2-16

The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma

2024-2-16

Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023

2024-2-8

Adjuvant Therapy in Renal Cell Cancer

2024-1-22

Efficacy, Effectiveness, and Safety of Interventions for Von Hippel-Lindau Associated Renal Cell Carcinoma: A Systematic Literature Review

2024-1-22

Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma

2023-12-29

Genomic and Transcriptomic Characteristics of Tumors of Patients with Metastatic Clear Cell Renal Cell Carcinoma Clinically Benefiting from First-Line Treatment with Ipilimumab Plus Nivolumab

2023-12-18

Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis

2023-12-18

Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies

2023-10-10

Fibrinogen Levels in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: Results of a Multicenter Prospective Trial

2023-10-6

Cystic Renal Lesions: A Systematic Review of Diagnosis and Treatment

2023-9-1

Antigenic targets in clear cell renal cell carcinoma

2023-8-1

MET Inhibitors for Papillary Renal Cell Carcinoma

2023-6-27

Clinical Trials Corner: The Challenge to Establish Optimal Treatment After Progression on Checkpoint Inhibitors

2023-6-16

Influences of Age and Comorbidities on Indication for Partial Nephrectomy: A Systematic Review

2023-6-12

Axitinib beyond first-line therapy of Metastatic Renal Cell Carcinoma: Real World Data from the STAR-TOR registry

2023-6-12

Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma

2023-5-26

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma

2023-3-23

Clinical Trials Corner: Raising the SABR to Renal Cell Carcinoma

2023-3-10

Erratum to: SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma

2023-2-17

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

2023-1-17

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time?

2022-12-30

Clinical Trials Corner: Another Approach to Treatment of Advanced Papillary Renal Cell Carcinoma

2022-12-29

Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor

2022-12-29

Activity of Immunotherapy Regimens on Primary Renal Tumours: A Systematic Review

2022-12-29

Systematic Review of Comparative Studies of 3D Models for Preoperative Planning in Minimally Invasive Partial Nephrectomy

2022-11-29

SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma1

2022-11-18

Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

2022-11-18

In Memoriam: Nicholas J. Vogelzang MD1

2022-11-18

Clinical Trials Corner: Optimizing Papillary Renal Cell Carcinoma Care

2022-10-14

EAU 2022 Highlights on Renal Cell Carcinoma

2022-10-7

Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current Clinical Trials and Future Directions

2022-9-16

Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma

2022-8-4

Clinical Trials Corner: Adding up in Adjuvant

2022-8-4

Geographical Differences in Kidney Cancer Outcomes of Patients Treated with Immunotherapy: A Systematic Review

2022-8-4

Disparities in Clinical Care and Research in Renal Cell Carcinoma

2022-7-29

Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer

2022-7-22

The Current Status of Kidney Cancer Urine Markers – A Systematic Review

2022-7-5

What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy

2022-6-24

Hereditary Renal Cell Carcinoma

2022-4-12